{
  "content": "Beta-blockers are a cornerstone treatment of patients with heart failure (HF) (1). Randomized trials with carvedilol (U.S. Carvedilol Study  and COPERNICUS [Carvedilol Prospective Randomized Cumulative Survival] [3,4]), metoprolol (MERIT-HF [Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure] ), bisoprolol (CIBIS-II [Cardiac Insufficiency Bisoprolol Study II] ), and nebivolol (SENIORS [Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure] ) showed that beta-blockers reduce morbidity and mortality in HF patients. As a result, these agents have received a Class IA recommendation in current HF guidelines (1). Atrial fibrillation (AF) is common in HF and occurs in 30% to 40% of all patients (8)",
  "source": "https://www.jacc.org/doi/10.1016/j.jchf.2012.09.002",
  "chunk_id": "edf0d064-5330-4d13-8ecd-8a62458a5cb8",
  "similarity_score": 0.18645673990249634,
  "query": "beta-blockers safety profile atrial fibrillation heart failure contraindications bradycardia hypotension",
  "rank": 41,
  "title": "Beta-blockers and outcome in heart failure and atrial fibrillation: A meta-analysis",
  "authors": "Michiel Rienstra, MD, PhD, Kevin Damman, MD, PhD, Bart A. Mulder, MD, Isabelle C. Van Gelder, MD, PhD, John J. V. McMurray, MD, Dirk J. Van Veldhuisen, MD, PhD",
  "year": "2013",
  "journal": "JACC: Heart Failure",
  "reference": "Rienstra, M., Damman, K., Mulder, B. A., Van Gelder, I. C., McMurray, J. J. V., & Van Veldhuisen, D. J. (2013). Beta-blockers and outcome in heart failure and atrial fibrillation: A meta-analysis. JACC: Heart Failure, 1(1), 29-36. https://doi.org/10.1016/j.jchf.2013.01.003",
  "doi": "10.1016/j.jchf.2013.01.003",
  "chunk_index": 8,
  "total_chunks": 82,
  "retrieved_at": "2025-07-24T21:57:55.188761"
}